Free Trial
NYSEARCA:THNR

Amplify Weight Loss Drug & Treatment ETF (THNR) Price, Holdings, & News

$21.22 +0.10 (+0.47%)
As of 04:10 PM Eastern

About Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR)

Key Stats

Today's Range
$21.09
$21.22
50-Day Range
$18.85
$23.60
52-Week Range
$18.56
$28.19
Volume
216 shs
Average Volume
3,365 shs
Market Capitalization
$3.18 million
Assets Under Management
$3.16 million
Dividend Yield
1.04%
Net Expense Ratio
0.59%
Aggregate Rating
Moderate Buy

ETF Overview

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

Amplify Weight Loss Drug & Treatment ETF Expenses

TypeTHNRTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.59%0.57%0.56%0.51%0.53%
Other Expenses0.00%0.57%0.48%0.56%0.52%
Total Expense0.59%0.73%0.72%0.73%0.71%
Fee Waiver0.00%-0.71%-0.49%-0.66%-0.54%
Net Expense0.59%0.60%0.63%0.58%0.60%
Receive THNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amplify Weight Loss Drug & Treatment ETF and its competitors with MarketBeat's FREE daily newsletter.

THNR ETF News Headlines

See More Headlines

THNR ETF - Frequently Asked Questions

Amplify Weight Loss Drug & Treatment ETF's stock was trading at $22.55 at the start of the year. Since then, THNR shares have decreased by 5.9% and is now trading at $21.22.
View the best growth stocks for 2025 here
.

Shares of THNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Weight Loss Drug & Treatment ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NICE (NICE) and Intellia Therapeutics (NTLA).

Fund Details

Issuer
Amplify
Fund Name
Amplify Weight Loss Drug & Treatment ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:THNR
Inception Date
5/21/2024
Fund Manager
Dustin Lewellyn, Ernesto Tong, Anand Desai
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Developed Markets
Region
Global
Number of Holdings
26

Fund Statistics

Assets Under Management
$3.16 million
Average Daily Volume
$0.00
Discount/Premium
0.05%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Amplify Investments LLC
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
GTS

Options

Optionable
N/A
Short Interest
300 shs

Miscellaneous

Beta
N/A
Creation Unit
10,000
Creation Fee
$300.00
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Top 10 THNR Holdings

THNR Sector Exposure

THNR Industry Exposure


This page (NYSEARCA:THNR) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners